中
About
Our Mission & Vision
Team
Leadership
Board of Directors
Scientific Advisory Board
Milestones
Pipeline
Ophthalmology
Neurology & Psychiatry
Partnership
Business Development
Our Partners
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
About
Our Mission & Vision
Team
Milestones
Pipeline
Ophthalmology
Neurology & Psychiatry
Partnership
Business Development
Our Partners
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
中
News
Press Releases
In The News
Media Room
May 25,2022
25
May 2022
AffaMed Therapeutics Announces Strategic Partnership with Primal Chemical to Market IOLs and DEXTENZA in Hong Kong and Macau
May 10,2022
10
May 2022
AffaMed Therapeutics Holds DEXTENZA Launch and Advisory Board Meeting in Macau
Apr 13,2022
13
April 2022
AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
Apr 13,2022
13
April 2022
VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
Feb 15,2022
15
February 2022
AffaMed Therapeutics Announces IND Clearance by US FDA for AM712 – a Novel Bispecific Biologic for the Treatment of Retinal Vascular Diseases
<<
<
1
2
3
4
5
>
>>
上一页
下一页
